Skip to main content
NVDA+1.07%AAPL+0.01%GOOGL+0.86%MSFT+0.91%AMZN+0.89%TSM+2.75%SPCX+7.63%META+0.32%AVGO+2.08%TSLA+1.08%SKHY-0.06%MU+0.54%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.50%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.16%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.88%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.94%USDZAR-0.90%USDPLN-0.87%USDMXN-0.75%AUDCHF+0.69%USDSEK-0.65%AUDJPY+0.59%CHFSEK-0.58%EURHKD+0.49%GBPCHF+0.48%USDDKK-0.47%GBPZAR-0.46%AUDUSD+0.43%EURZAR-0.42%EURCNH+0.42%GBPTRY+0.41%AUDCAD+0.41%GBPJPY+0.41%NOKJPY+0.41%EURPLN-0.39%NZDMXN-0.39%EURCHF+0.36%USDNOK-0.35%AUDNZD+0.34%GBPHKD+0.32%GBPUSD+0.31%GBPCAD+0.30%EURSGD+0.29%EURJPY+0.29%GBPMXN-0.28%NZDCHF+0.27%CHFNOK-0.27%AUDDKK-0.27%GBPSGD+0.25%SGDJPY+0.25%EURAUD-0.24%GBPNZD+0.22%EURCZK-0.21%NZDJPY+0.21%EURUSD+0.19%USDSGD-0.19%CADCHF+0.18%USDCHF+0.18%EURCAD+0.18%NZDSGD+0.17%EURSEK-0.17%USDILS+0.16%GBPAUD-0.16%AUDNOK-0.15%EURNOK+0.14%USDJPY+0.13%CHFSGD-0.12%CADJPY+0.12%EURNZD+0.11%EURGBP-0.11%USDTRY+0.10%NZDUSD+0.09%NZDCAD+0.08%CHFJPY-0.07%USDCNH-0.06%USDTHB+0.06%USDCOP-0.04%EURDKK+0.01%AUDSGD+0.01%USDHKD+0.01%USDCAD0.00%UKOIL-2.51%USOIL-2.15%W1+0.99%C1+0.90%GAUUSD+0.89%XAUUSD+0.89%COFFEE+0.87%GAGUSD+0.85%XAGUSD+0.85%COCOA-0.80%COTTON+0.75%S1+0.63%BTCUSD+0.59%ETHUSD+6.15%USDTUSD-0.04%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.21%ZECUSDT+2.63%DOGEUSD-1.82%XMRUSDT-0.74%LINKUSD+3.21%XLMUSD+0.43%BCHUSDT+0.38%UNIUSD-1.99%LTCUSD-4.60%SUIUSD-0.75%HBARUSDT-0.14%TONUSD+12.52%TAOUSDT-0.71%AAVEUSD-0.89%DOTUSDT+0.44%ICPUSDT-3.87%ONDOUSDT+0.10%WLDUSDT+1.18%ARBUSDT-3.21%JUPUSDT-0.14%ATOMUSDT-0.52%INJUSDT+1.01%STXUSDT+0.08%FETUSDT-2.13%SEIUSDT-0.61%PYTHUSDT+1.12%TIAUSDT-1.21%IMXUSDT-1.75%GRTUSDT-0.48%OPUSDT-2.99%WIFUSDT+0.80%IOTAUSDT+3.93%AXSUSDT-0.94%POLUSDT+1.72%FARTCOINUSDT+2.25%EOSUSDT+3.59%DYDXUSDT-1.69%GALAUSDT-0.52%ORDIUSDT+1.31%NOTUSDT+1.29%RONINUSDT+4.44%NVDA+1.07%AAPL+0.01%GOOGL+0.86%MSFT+0.91%AMZN+0.89%TSM+2.75%SPCX+7.63%META+0.32%AVGO+2.08%TSLA+1.08%SKHY-0.06%MU+0.54%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.50%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.16%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.88%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.94%USDZAR-0.90%USDPLN-0.87%USDMXN-0.75%AUDCHF+0.69%USDSEK-0.65%AUDJPY+0.59%CHFSEK-0.58%EURHKD+0.49%GBPCHF+0.48%USDDKK-0.47%GBPZAR-0.46%AUDUSD+0.43%EURZAR-0.42%EURCNH+0.42%GBPTRY+0.41%AUDCAD+0.41%GBPJPY+0.41%NOKJPY+0.41%EURPLN-0.39%NZDMXN-0.39%EURCHF+0.36%USDNOK-0.35%AUDNZD+0.34%GBPHKD+0.32%GBPUSD+0.31%GBPCAD+0.30%EURSGD+0.29%EURJPY+0.29%GBPMXN-0.28%NZDCHF+0.27%CHFNOK-0.27%AUDDKK-0.27%GBPSGD+0.25%SGDJPY+0.25%EURAUD-0.24%GBPNZD+0.22%EURCZK-0.21%NZDJPY+0.21%EURUSD+0.19%USDSGD-0.19%CADCHF+0.18%USDCHF+0.18%EURCAD+0.18%NZDSGD+0.17%EURSEK-0.17%USDILS+0.16%GBPAUD-0.16%AUDNOK-0.15%EURNOK+0.14%USDJPY+0.13%CHFSGD-0.12%CADJPY+0.12%EURNZD+0.11%EURGBP-0.11%USDTRY+0.10%NZDUSD+0.09%NZDCAD+0.08%CHFJPY-0.07%USDCNH-0.06%USDTHB+0.06%USDCOP-0.04%EURDKK+0.01%AUDSGD+0.01%USDHKD+0.01%USDCAD0.00%UKOIL-2.51%USOIL-2.15%W1+0.99%C1+0.90%GAUUSD+0.89%XAUUSD+0.89%COFFEE+0.87%GAGUSD+0.85%XAGUSD+0.85%COCOA-0.80%COTTON+0.75%S1+0.63%BTCUSD+0.59%ETHUSD+6.15%USDTUSD-0.04%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.21%ZECUSDT+2.63%DOGEUSD-1.82%XMRUSDT-0.74%LINKUSD+3.21%XLMUSD+0.43%BCHUSDT+0.38%UNIUSD-1.99%LTCUSD-4.60%SUIUSD-0.75%HBARUSDT-0.14%TONUSD+12.52%TAOUSDT-0.71%AAVEUSD-0.89%DOTUSDT+0.44%ICPUSDT-3.87%ONDOUSDT+0.10%WLDUSDT+1.18%ARBUSDT-3.21%JUPUSDT-0.14%ATOMUSDT-0.52%INJUSDT+1.01%STXUSDT+0.08%FETUSDT-2.13%SEIUSDT-0.61%PYTHUSDT+1.12%TIAUSDT-1.21%IMXUSDT-1.75%GRTUSDT-0.48%OPUSDT-2.99%WIFUSDT+0.80%IOTAUSDT+3.93%AXSUSDT-0.94%POLUSDT+1.72%FARTCOINUSDT+2.25%EOSUSDT+3.59%DYDXUSDT-1.69%GALAUSDT-0.52%ORDIUSDT+1.31%NOTUSDT+1.29%RONINUSDT+4.44%
OT

Oruka Therapeutics, Inc. (ORKA)

NASDAQ • Healthcare

$84.38
-$0.14 (-0.2%)
Market closed

Last close at October 5, 2026 at 20:00 UTC

Open$84.52
Day Range$81.83 - $85.23
Avg. Volume (3M)999.5K
Market Cap$5B
52 Week Range
$19.89$115.52
Next EarningsIn 36 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$132.8M
EPS (TTM)
-$2.47
ROA (TTM)
-11.66%
Current Ratio
38.51
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+26.2%Q1 2026-$0.45
+12.2%Q2 2026-$0.48
-7.3%Q3 2026-$0.55
Next

Nov 11

in 36 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -7.3%

Oruka Therapeutics’ preliminary results for the second fiscal quarter of 2026 showed adjusted EPS of -$0.55, which trailed the -$0.51 estimate (-7%), when it reported on August 10, 2026. On a year-over-year basis, adjusted EPS was down -19.6% from -$0.46 a year ago, alongside a GAAP net loss of roughly $41.2 million, down -67.7% from roughly $24.6 million in the prior-year period. The company also posted GAAP operating income of around -$50.1 million for the quarter, and it reported negative operating cash flow of about $33.1 million. For the next period, consensus calls for EPS of -$0.59.

View full earnings history

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops monoclonal antibody medicines for psoriasis and other inflammatory and immunology conditions. In qualitative terms, it is a clinical-stage business built around a small pipeline of named antibody programs rather than a marketed-product portfolio.

Name
Oruka Therapeutics, Inc.
CEO
Lawrence Otto Klein
Website
www.orukatx.com
Industry
Healthcare
Employees
68

Today's Snapshot

AI-generated

ORKA closed slightly lower at 84.38.

Trading Volume

Below 10d avg (1.1M)

629.5K

vs S&P 500 Today

Underperforming Market

-0.83%

Updated: October 6, 2026 at 12:10 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
ORKA presents a cautious sell bias with the stock below short and medium moving averages even though the long-term averages remain higher. Momentum indicators are negative overall, with MACD depressed and short-term momentum falling, while stochastic and Williams readings show short-lived oversold interest. Trend strength is moderate by ADX, volatility is elevated as ATR is several percent of price, and OBV does not confirm buying pressure. Technical takeaway: Sell — short-to-medium term momentum and moving averages weigh on the stock despite longer-term averages holding higher levels.
All signals
  • EMA (5 indicators)$66.08 - $90.62
    Sell
  • RSI (14)38.07
    Neutral
  • Stochastic %K (14, 3, 3)17.44
    Buy
  • MACD Level (12, 26)-3.37
    Sell

Peers & Related Assets

KODKodiak Sciences Inc.
$93.81-0.7%
NRIXNurix Therapeutics, Inc.
$22.88-0.5%
URGNUroGen Pharma Ltd.
$42.78+3.3%
XNCRXencor, Inc.
$25.63+3.2%
RAPPRapport Therapeutics, Inc. Common Stock
$32.19+0.1%
ANABAnaptysBio, Inc.
$49.2+1.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.